Parkwood LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 116.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,469 shares of the biopharmaceutical company’s stock after acquiring an additional 8,869 shares during the quarter. Parkwood LLC’s holdings in Gilead Sciences were worth $1,334,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in GILD. BlackRock Inc. lifted its holdings in shares of Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the period. FMR LLC lifted its holdings in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. Hedge funds and other institutional investors own 75.94% of the company’s stock.
GILD has been the subject of a number of research reports. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price for the company in a report on Friday, October 13th. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. BMO Capital Markets decreased their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Credit Suisse Group reissued a “buy” rating and issued a $82.00 price target on shares of Gilead Sciences in a report on Thursday, December 7th. Finally, Mizuho boosted their price target on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $85.03.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down $0.04 on Friday, hitting $79.02. The company had a trading volume of 6,342,448 shares, compared to its average volume of 8,150,000. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The stock has a market capitalization of $103,190.00, a PE ratio of 8.99, a price-to-earnings-growth ratio of -1.68 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the previous year, the business earned $2.75 earnings per share. The firm’s revenue for the quarter was down 13.2% on a year-over-year basis. sell-side analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.63%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s payout ratio is currently 23.66%.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the sale, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 461,666 shares of company stock valued at $34,072,567. 1.30% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.thelincolnianonline.com/2018/01/13/gilead-sciences-inc-gild-holdings-lifted-by-parkwood-llc-updated.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.